New drug aims to boost blood counts in rare pre-leukemia condition
NCT ID NCT06240754
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study tests whether enasidenib, a drug that blocks a faulty IDH2 protein, can safely improve blood cell counts in people with clonal cytopenia of undetermined significance (CCUS). CCUS causes low blood counts and raises the risk of blood cancers. The trial enrolls 15 adults with IDH2 mutations and will monitor blood counts and side effects over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CCUS CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug revive blood cell production in a Pre-Leukemic condition?
- Can a simple blood test predict leukemia risk after cancer therapy?
- Could a common vitamin help fix low blood counts?
- New registry aims to unlock secrets of rare blood cancers
- Could cholesterol drugs fight blood cancer? small study tests idea
- Can a cancer drug stop a blood disorder before it turns deadly?